Gossamer Bio Company Insiders

GOSS Stock  USD 2.54  0.00  0.00%   
Gossamer Bio employs about 144 people. The company is managed by 18 executives with a total tenure of roughly 24 years, averaging almost 1.0 years of service per executive, having 8.0 employees per reported executive. Breaking down Gossamer Bio's management performance can provide insight into the firm performance.
Faheem Hasnain  Chairman
Executive Chairman of the Board, Co-Founder
Christian Waage  President
Executive Vice President General Counsel

Insider Sentiment 50

 Impartial

 
Selling
 
Buying

Latest Trades

2024-06-24Richard ArandaDisposed 1908 @ 0.66View
2024-06-21Faheem HasnainAcquired 372000 @ 0.67View
2024-03-27Faheem HasnainDisposed 23172 @ 1.16View
2024-03-18Richard ArandaDisposed 4018 @ 1.33View
2023-11-13Bryan GiraudoAcquired 200000 @ 0.56View
2023-06-22Richard ArandaDisposed 1814 @ 1.29View
2023-04-04Bryan GiraudoAcquired 55000 @ 1.02View
2023-03-22Faheem HasnainAcquired 440500 @ 1.14View
2023-03-20Faheem HasnainAcquired 168683 @ 1.03View
2023-03-16Laura CarterDisposed 6029 @ 1.1View
Monitoring Gossamer Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gossamer Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Gossamer Stock please use our How to Invest in Gossamer Bio guide.

Gossamer Bio's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Gossamer Bio's future performance. Based on our forecasts, it is anticipated that Gossamer will maintain a workforce of slightly above 140 employees by February 2026.
 
Covid

Gossamer Bio Management Team Effectiveness

The company has return on total asset (ROA) of (0.3425) % which means that it has lost $0.3425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.8337) %, meaning that it created substantial loss on money invested by shareholders. Gossamer Bio's management efficiency ratios could be used to measure how well Gossamer Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2026. Return On Capital Employed is likely to gain to -0.24 in 2026. Non Current Assets Total is likely to gain to about 9.2 M in 2026, whereas Total Assets are likely to drop slightly above 299.4 M in 2026.
Common Stock Shares Outstanding is likely to gain to about 273.2 M in 2026, whereas Net Loss is likely to drop (216.8 M) in 2026.
Gossamer Bio has a total of 231.46 Million outstanding shares. The majority of Gossamer Bio outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gossamer Bio to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gossamer Bio. Please pay attention to any change in the institutional holdings of Gossamer Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2017-03-31
Previous Quarter
227.3 M
Current Value
228 M
Avarage Shares Outstanding
99.7 M
Quarterly Volatility
78.5 M
 
Covid
Some institutional investors establish a significant position in stocks such as Gossamer Bio in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Gossamer Bio, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Gossamer Bio Workforce Comparison

Gossamer Bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,718. Gossamer Bio holds roughly 144 in number of employees claiming about 8% of equities under Health Care industry.

Gossamer Bio Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gossamer Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gossamer Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Gossamer Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
7.0
7
1
 957,000 
 1,908 
2024-03-01
1.4
7
5
 3,553,750 
 44,068 
2023-06-01
1.2727
28
22
 2,244,906 
 1,899,164 
2023-03-01
1.3333
4
3
 437,500 
 21,156 
2022-12-01
1.5
6
4
 1,386,000 
 19,266 
2022-09-01
4.0
4
1
 166,433 
 8,808 
2022-06-01
5.0
10
2
 300,000 
 3,040 
2022-03-01
1.0
6
6
 1,675,000 
 58,038 
2021-06-01
0.7222
13
18
 319,640 
 637,773 
2021-03-01
2.6667
8
3
 892,500 
 16,471 
2019-12-01
0.4
2
5
 41,994 
 87,988 
2019-09-01
0.4
4
10
 22,121 
 450,000 
2019-03-01
0.6786
19
28
 16,062,639 
 69,950,470 

Gossamer Bio Notable Stakeholders

A Gossamer Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gossamer Bio often face trade-offs trying to please all of them. Gossamer Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gossamer Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Faheem HasnainExecutive Chairman of the Board, Co-FounderProfile
Christian WaageExecutive Vice President General CounselProfile
Deanna WeberVice President of Human ResourcesProfile
Bryan GiraudoCOO CFOProfile
Colin RowlingsSenior CMCProfile
Robert SmithChief OfficerProfile
Matt CravetsSenior BiometricsProfile
Jeff BoernekeGeneral SecretaryProfile
Louis ChericoSenior TreasuryProfile
Richard MDChief OfficerProfile
Mario OrlandoSenior PlanningProfile
Caryn PetersonExecutive AffairsProfile
Laura CarterChief OfficerProfile
Jeanine AnthonySenior MarketingProfile
Kelly DawsonSenior LeadProfile
Robert RoscignoSenior DiseaseProfile
Christian JDExecutive AdministrationProfile
Lisa NolanMD IrelandProfile
String symbol = request.getParameter("s");

About Gossamer Bio Management Performance

The success or failure of an entity such as Gossamer Bio often depends on how effective the management is. Gossamer Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gossamer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gossamer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.16)(0.17)
Return On Capital Employed(0.25)(0.24)
Return On Assets(0.16)(0.17)
Return On Equity(2.20)(2.31)
Please note, the imprecision that can be found in Gossamer Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gossamer Bio. Check Gossamer Bio's Beneish M Score to see the likelihood of Gossamer Bio's management manipulating its earnings.

Gossamer Bio Workforce Analysis

Traditionally, organizations such as Gossamer Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gossamer Bio within its industry.

Gossamer Bio Manpower Efficiency

Return on Gossamer Bio Manpower

Revenue Per Employee796.5K
Revenue Per Executive6.4M
Net Loss Per Employee392.6K
Net Loss Per Executive3.1M
Working Capital Per Employee1.8M
Working Capital Per Executive14.7M

Additional Tools for Gossamer Stock Analysis

When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.